SCHEMBL25221496

SCHEMBL25221496

Cn1nnc2cc(N)c(Cl)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 4/20 0.41
▸ SLC9A1 P19634 1/20 0.41
▸ HCAR3 P49019 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ NPC1 O15118 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ CASP9 P55211 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ CASP8 Q14790 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ MGAM O43451 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848287 0.84 KEAP1 (0.47) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL25556243 0.79 KEAP1 (0.47) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL25559702 0.79 ATAD2 (0.44) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL8562891 0.76 KEAP1 (0.47) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL25555580 0.75 KEAP1 (0.39) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL10777056 0.74 KEAP1 (0.41) KEAP1SLC9A1HCAR3GAANPC1
SCHEMBL31475765 0.74 HCAR3 (0.41) KEAP1SLC9A1HCAR3NPC1KDM4E
SCHEMBL922757 0.73 SLC9A1 (0.53) KEAP1SLC9A1HCAR3NPC1KDM4E
SCHEMBL210242 0.73 NPC1 (0.54) KEAP1SLC9A1HCAR3NPC1KDM4E
Hydrochloric Acid SCHEMBL30764982 0.72 KDM4E (0.53) KEAP1SLC9A1HCAR3NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 KEAP1 1148/4885SLC9A1 4747/4885HCAR3 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback